Biolevate
Founded in 2023 in Paris, France, Biolevate uses AI to help medical writers create and manage research and regulatory documents.
Position in SVTR
Snapshot 2026-10-22- Startup SignalsTop 50%↓28
- Life SciencesTop 50%↓2
- Text / NLP#4of 11–
About
Founded in 2023 in Paris, France, Biolevate uses AI to help medical writers create and manage research and regulatory documents. Recently selected for Station F's Future 40 list, the company applies NLP and computer vision to streamline the creation and management of research and compliance documents.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-09-22Series A$34M
Investors · RAISE France, Orange Ventures, MSD Global Health Innovation, Station F, EQT VenturesSource · biolevate.com ↗
- 2024-11New funding round$6M
Investors · Bpifrance, EQT VenturesSource · SVTR Weekly #081
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Biolevate
AI that helps medical writers create and manage research and regulatory documents.
Series A · $41M · 2026-09
$41M
United States
BusinessLatest roundTotal raisedDate- Rad AI
Uses artificial intelligence to help radiologists automatically generate report summaries and manage patient follow-ups
Series C · $110M · 2025-02
$110M - Layer Health
Uses AI to analyze unstructured data in patient records, helping providers and researchers with quality reporting and clinical research
Series A · $25M · 2025-03
$25M - Percipio Health
AI-based patient health monitoring and management via smartphones
Series A · $20M · 2025-01
$20M
Europe
BusinessLatest roundTotal raisedDate- Quibim
AI analysis of MRI, CT and PET medical images to help physicians diagnose disease
Series A · $50M · 2025-02
$50M - Deciphex
Digital pathology software using AI to help pathologists analyze medical samples more efficiently
Series C · $32M · 2025-01
$32M - Cradle
AI that helps scientists design and engineer proteins faster and more cost-effectively
Undisclosed · $106M · 2024-12
$106M
Other / unspecified
BusinessLatest roundTotal raisedDate- Nucleai
Uses AI to analyze pathology images for medical research and clinical diagnosis
Undisclosed · $14M · 2024-04
$14M - Cureskin
App using AI analysis to deliver dermatologist-designed personalized skincare and haircare plans
Series B · $20M · 2024-03
$20M - Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 25 at a nearby stage · 1 in Western Europe
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 10 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 9 at a nearby stage · 3 in Western Europe
Request intro →LifeX Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Western Europe
Request intro →Index Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.